US FDA may be calling for increasingly demanding device study designs, signals draft guidance
This article was originally published in SRA
Executive Summary
A recently issued US Food and Drug Administration draft guideline on what sponsors should consider when designing pivotal clinical investigations signals that the "FDA will be requesting, or perhaps requiring, increasingly demanding study designs", says lawyer Jennifer D Newberger, of Hyman, Phelps & McNamara1-4.